Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986263 in healthy participants
NCT03142165Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2017
- Primary completion
- Nov 2017
- Modality
- Antisense DNA, Lipid-based Nanoparticles, Conjugated siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in fibrosis comparing BMS-986263 with Placebo (2 arms). Primary endpoints: Adverse Events (AE) at 28 days, Serious Adverse Events (SAE) at 30 days and 5 more. Started May 2017; status: completed.
02
Drugs
ND-L02-s0201
03
Conditions
fibrosis
Beyond the preview
Go deeper on NCT03142165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03142165.